Browse studies
Find your next paid study
3 recruiting studies matching your filters
Phase 2
An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1
An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as fi…
Unresectable Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck Cancer
Estimated
~$10 – $7,500
BioNTech SENCT04534205
Phase 2
A Phase 2 Trial of PD-L1 t-haNK, NAI IL-15 Superagonist (Anktiva), and Cetuximab for Immunotherapy-treated Patients With Recurrent, Metastatic HNSCC (QUILT-505)
The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), NAI (a manufactured protein t…
Head and Neck CancerHead and Neck Squamous Cell CarcinomaMetastatic Head and Neck Cancer+3 more
Estimated
~$10 – $7,500
Glenn J. HannaNCT06239220
Phase 1
Feasibility Trial of Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a feasibility trial studying anti-PD-1 therapy (Pembrolizumab) among patients with R/M HNSCC, delivered with ultrasound-induced microbubble cavitation,…
Head and Neck CancerHead and Neck Small Cell CarcinomaMetastatic Head and Neck Cancer+1 more
Estimated
~$10 – $6,250
Thomas Jefferson UniversityNCT07501650